This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/drugbank/
n23http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
n9http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/pdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/bindingdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00119/identifier/pubchem-compound/

Statements

Subject Item
n2:DB00119
rdf:type
n3:Drug
n3:description
An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
n3:group
nutraceutical approved
n3:indication
For nutritional supplementation, also for treating dietary shortage or imbalance
owl:sameAs
n14:DB00119 n23:DB00119
dcterms:title
Pyruvic acid
adms:identifier
n11:19473 n12:32816 n15:1060 n16:46505692 n17:C00022 n18:PYR n19:1031 n20:Pyruvic_acid n21:DB00119 n22:PA164778686
n3:mechanismOfAction
Pyruvate serves as a biological fuel by being converted to acetyl coenzyme A, which enters the tricarboxylic acid or Krebs cycle where it is metabolized to produce ATP aerobically. Energy can also be obtained anaerobically from pyruvate via its conversion to lactate. Pyruvate injections or perfusions increase contractile function of hearts when metabolizing glucose or fatty acids. This inotropic effect is striking in hearts stunned by ischemia/reperfusion. The inotropic effect of pyruvate requires intracoronary infusion. Among possible mechanisms for this effect are increased generation of ATP and an increase in ATP phosphorylation potential. Another is activation of pyruvate dehydrogenase, promoting its own oxidation by inhibiting pyruvate dehydrogenase kinase. Pyruvate dehydrogenase is inactivated in ischemia myocardium. Yet another is reduction of cytosolic inorganic phosphate concentration. Pyruvate, as an antioxidant, is known to scavenge such reactive oxygen species as hydrogen peroxide and lipid peroxides. Indirectly, supraphysiological levels of pyruvate may increase cellular reduced glutathione.
n3:synonym
CH3COCOOH alpha-Ketopropionic acid Acide pyruvique 2-Oxopropansaeure a-Ketopropionic acid Pyruvic acid Pyroracemic acid Brenztraubensaeure BTS alpha-Oxopropionsaeure α-ketopropionic acid Acetylformic acid 2-ketopropionic acid 2-Oxopropionsaeure 2-Oxopropanoic acid
n3:toxicity
Those taking large doses of supplemental pyruvate—usually greater than 5 grams daily—have reported gastrointestinal symptoms, including abdominal discomfort and bloating, gas and diarrhea. One child receiving pyruvate intravenously for restrictive cardiomyopathy died.
n3:synthesisReference
Tadamitsu Kiyoura, "Process for producing salts of pyruvic acid." U.S. Patent US4242525, issued December, 1965.
n5:hasConcept
n6:M0028719
foaf:page
n9:pyr_0218.shtml
n3:IUPAC-Name
n4:271B4711-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4717-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4716-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4713-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4714-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4715-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4727-363D-11E5-9242-09173F13E4C5 n4:271B470F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B470D-363D-11E5-9242-09173F13E4C5 n4:271B4710-363D-11E5-9242-09173F13E4C5 n4:271B472A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B470E-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B472B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B471D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B471E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4718-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4719-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B471B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B471A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B471C-363D-11E5-9242-09173F13E4C5
n3:absorption
Pyruvate is absorbed from the gastrointestinal tract from whence it is transported to the liver via the portal circulation.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
127-17-3
n3:category
n3:Bioavailability
n4:271B4723-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B4729-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4725-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4726-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4728-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4722-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4721-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4724-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4712-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B471F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4720-363D-11E5-9242-09173F13E4C5